Auranofin. New oral gold compound for treatment of rheumatoid arthritis.
AUTOR(ES)
Finkelstein, A E
RESUMO
Eight patients with rheumatoid arthritis were treated with SK & F D-39162 (auranofin), a new oral gold compound which was effective in suppressing adjuvant-induced arthritis in rats. Clinical and humoral parameters were studied during a 3-month period of drug administration followed by a 3-month period under placebo. The drug was absorbed, well tolerated, and its action was manifested by a drop in the mean IgG blood levels in the third week of treatment accompanied by clinical improvement after 5 weeks of oral gold intake. Together with IgG changes, an increase of the albumin ratio was observed, as well as a decrease of alpha2-globulin and rheumatoid factor titres. From a total number of 60 swollen joints found initially in the 8 patients only 17 were swollen at week 12 and 9 at week 15. Although the number of patients treated was too small to allow definite conclusions, a follow-up study under placebo of clinical and laboratory changes in the same patients during another 3-month period showed that IgG serum levels rapidly reverted preceding a flare up of disease activity after withdrawal of the drug. This confirmed a direct role in cause-effect relation played by the new oral gold compound.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1006549Documentos Relacionados
- Comparative toxicity of gold preparations in treatment of rheumatoid arthritis.
- Fall in immune complex levels during gold treatment of rheumatoid arthritis.
- Gold colitis induced by auranofin treatment of rheumatoid arthritis: case report and review of the literature.
- Contact allergy to gold after systemic administration of gold for rheumatoid arthritis.
- Plasma levels and urinary excretion of gold during routine treatment of rheumatoid arthritis.